With a $9 billion market cap and a stock that has shot up 1,167% over
the past twelve months, it is not too surprising that expectations are
high for Intercept Pharmaceuticals (NASDAQ: ICPT )
and investors are nervous about even the slightest hint of trouble in
the clinical pipeline. To that end, it would seem that investors are
more nervous about the prospect of a cardiovascular safety issue in the
Phase II study of lead compound obeticholic acid (or OCA) than cheered
by another strong trial outcome in primary biliary cirrhosis.
Please read more here:
Is Intercept Pharmaceuticals, Inc. Overvalued?
No comments:
Post a Comment